| Ytd | -62.07% | |
| 1y | -92.83% |
| Open | 4.19 | Prev Close | 4.31 | Low | 4.19 | High | 4.53 | Mkt Cap | 6.48M |
| Vol | 76.57K | Avg Vol | 1.29M | EPS | -17.51 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.11 | 200-d Avg | 13.44 | 1yr Est | 0.00 |
NXTS News
Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug disco
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Ne
US stocks lower, Nasdaq falls 500 points. Dow down 0.04%, Nasdaq 1.91%, S&P 500 1.27%. Consumer
US stocks down as Dow falls 300 points, while S&P 500 and NASDAQ also decrease. Consumer staples
Nexentis stock surged on AI drug discovery news before falling after announcing a $2.9 million offer
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi
US stocks rise, Dow up over 200 points. Financial shares jump 0.9% while communication services stoc
Under this initiative, MitoCareX intends to combine two complementary and independently validated ca
Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug disco
Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expe
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open